CoChat

Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations

Butler, Javed, Anker, Stefan D, Filippatos, Gerasimos, Usman, Muhammad Shariq, Ferreira, Joao Pedro, Zannad, Faiez, Packer, Milton · 2021 · European Heart Journal

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Hospitalization for heart failure marks a fundamental change in the natural history of the disease and portends a poor prognosis for the patients. For those without a history of heart failure, a hospitalization signals development of new onset heart failure that is associated with 40–50% 5-year mortality risk.1 Amongst those with a previous history of heart failure, worsening symptoms leading to hospitalization are associated with ∼20–25% 1 year mortality risk, a ∼20% 4-week readmission risk and a ∼50% 6-month readmission risk.1 In observational studies, these risks are apparent whether a person has heart failure with reduced or preserved ejection fraction.2 Recent clinical trials have demonstrated that worsening heart failure is associated with the highest absolute risk of heart failure hospitalization, followed by chronic heart failure with reduced ejection fraction, and then chronic heart failure with preserved ejection fraction in the outpatient setting. Relative to patients with manifest heart failure, the absolute risk of heart failure hospitalizations is lower in populations with chronic kidney disease and diabetes without prevalent heart failure, but these patients nevertheless are at a higher risk than those without these comorbidities. Indeed, in patients with diabetes mellitus, the risk for heart failure has been shown to be higher and less amenable to reduction with risk factor control than myocardial infarction and diabetes.3 Besides portending risk, these hospitalizations are associated with high costs, both to an individual as well as the society, accounting for most of the overall annual direct cost of care related to heart failure.1 Thus, prevention of hospitalizations for heart failure is an important clinical, patient-centric and societal goal.

Overview

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehab704

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Cited by

See all 19

Metadata

Authors
Butler, J., Anker, S. D., Filippatos, G., Usman, M. S., Ferreira, J. P., Zannad, F., & Packer, M.
Affiliations
  • University of Mississippi Medical Center (US)
  • Berlin-Brandenburger Centrum für Regenerative Therapien (DE)
  • National and Kapodistrian University of Athens (GR)
  • Université de Lorraine, Inserm INI-CRCT, CHRU , 34 Cr Léopold, Nancy 54000, France
  • Inserm (FR)
  • Baylor Heart and Vascular Institute , 621 North Hall Street, Dallas, TX, USA
Corresponding author
Butler, Javed
Venue
European Heart Journal
Published
2021-10-30
Volume
42
Issue
48
Pages
4887-4890
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W3210386024
Cited by
18
References
17
Citations by year
2026: 1 · 2025: 1 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 1
FWCI
2.70
Type
journal article
Language
en
Open access
closed
Locations
  • European Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
heart failure hospitalization, heart failure outcomes, heart failure with reduced ejection fraction, chronic kidney disease, diabetes mellitus
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Glucose, Heart Failure, Humans, Sodium, Symporters

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. https://app.cochat.ai/papers/10.1093/eurheartj/ehab704
The paper
Butler, J., Anker, S. D., Filippatos, G., Usman, M. S., Ferreira, J. P., Zannad, F., & Packer, M. (2021). Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. European Heart Journal. https://doi.org/10.1093/eurheartj/ehab704

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.